Global gene expression profiling in early-stage polycystic kidney disease in the Han:SPRD Cy rat identifies a role for RXR signaling

American Journal of Physiology - Renal Physiology

Volumn 300, Issue 1, 2011, Pages

  Kugita, Masanori ^a   Nishii, Kazuhiro ^a   Morita, Miwa ^a   Yoshihara, Daisuke ^a   Kowa Sugiyama, Hiroe ^a   Yamada, Kouji ^a   Yamaguchi, Tamio ^a   Wallace, Darren P ^b   Calvet, James P ^b   Kurahashi, Hiroki ^a   Nagao, Shizuko ^a  

^a FUJITA HEALTH UNIVERSITY   (Japan)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

ADPKD; Proliferation; Retinoid X receptor

Indexed keywords

CYCLINE; RETINOID X RECEPTOR; TRANSCRIPTION FACTOR PITX2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; EPITHELIUM CELL; GENE; GENE EXPRESSION PROFILING; KIDNEY POLYCYSTIC DISEASE; MICROARRAY ANALYSIS; MORPHOGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PKDR1 GENE; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE; UPREGULATION;

EID: 78651296357     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00470.2010     Document Type: Article

References (58)

1. Brown JH, Bihoreau MT, Hoffmann S, Kränzlin B, Tychinskaya I, Obermüller N, Podlich D, Boehn SN, Kaisaki PJ, Megel N, Danoy P, Copley RR, Broxholme J, Witzgall R, Lathrop M, Gretz N, Gauguier D. Missense mutation in sterile alpha motif of novel protein SamCystin is associated with polycystic kidney disease in (cy/+) rat. J Am Soc Nephrol 16: 3517-3526, 2005.
2. Buentig N, Stoerkel S, Richter E, Dallmann I, Reitz M, Atzpodien J. Predictive impact of retinoid X receptor-alpha-expression in renal-cell carcinoma. Cancer Biother Radiopharm 19: 331-342, 2004.
3. Burrage PS, Schmucker AC, Ren Y, Sporn MB, Brinckerhoff CE. Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression. Arthritis Res Ther 10: R139, 2008.
4. Burtey SJ, Riera M, Fontés M. Overexpression of complement-component genes in Han:SPRD rats a model of polycystic kidney disease. Kidney Int 73: 1324-1325, 2008.
5. Cesario RM, Stone J, Yen WC, Bissonnette RP, Lamph WW. Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer. Cancer Lett 240: 225-233, 2006.
6. Cowley BD Jr, Ricardo SD, Nagao S, Diamond JR. Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats. Kidney Int 60: 2087-2096, 2001.
7. Cowley BD Jr, Gudapaty S, Kraybill AL, Barash BD, Harding MA, Calvet JP, Gattone VH 2nd. Autosomal-dominant polycystic kidney disease in the rat. Kidney Int 43: 522-534, 1993.
8. Crowe DL, Chandraratn RA. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-α is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res 6: R546-R555, 2004.
9. Fischer DC, Jacoby U, Pape L, Ward CJ, Kuwertz-Broeking E, Renken C, Nizze H, Querfeld U, Rudolph B, Mueller-Wiefel DE, Bergmann C, Haffner D. Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD). Nephrol Dial Transplant 24: 1819-1827, 2009.
10. Fürstenberger G, Krieg P, Müller-Decker K, Habenicht AJ. What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? Int J Cancer 119: 2247-2254, 2006.
11. Gattone VH 2nd, Cowley BD Jr, Barash BD, Nagao S, Takahashi H, Yamaguchi T, Grantham JJ. Methylprednisolone retards the progression of inherited polycystic kidney disease in rodents. Am J Kidney Dis 25: 302-313, 1995.
12. Gile RD, Cowley BD Jr, Gattone 2nd VH, O'Donnell MP, Swan SK, Grantham JJ. Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J Kidney Dis 26: 501-507, 1995.
13. Hanaoka K, Qian F, Boletta A, Bhunia AK, Piontek K, Tsiokas L, Sukhatme VP, Guggino WB, Germino GG. Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature 408: 990-994, 2000.
14. Igarashi P, Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 13: 2384-2398, 2002.
15. Islam MR, Puri S, Rodova M, Magenheimer BS, Maser RL, Calvet JP. Retinoic acid-dependent activation of the polycystic kidney disease-1 (PKD1) promoter. Am J Physiol Renal Physiol 295: F1845-F1854, 2008.
16. Klopper JP, Sharma V, Berenz A, Hays WR, Loi M, Pugazhenthi U, Said S, Haugen BR. Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression. Cancer Genet Cytogenet 197: 39-45, 2010.
17. Lal M, Song X, Pluznick JL, Di Giovanni V, Merrick DM, Rosenblum ND, Chauvet V, Gottardi CJ, Pei Y, Caplan MJ. Polycystin-1 C-terminal tail associates with beta-catenin and inhibits canonical Wnt signaling. Hum Mol Genet 17: 3105-3117, 2008.
18. Lee SM, Lee JY, Choi JE, Lee SY, Park JY, Kim DS. Epigenetic inactivation of retinoid X receptor genes in non-small cell lung cancer and the relationship with clinicopathologic features. Cancer Genet Cytogenet 197: 39-45, 2010.
19. Manzano VM, Puyol MR, Puyol DR, Cazaña FJ. Tretinoin prevents age-related renal changes and stimulates antioxidant defenses in cultured renal mesangial cells. J Pharmacol Exp Ther 289: 123-132, 1999.
20. Manzano VM, Muñoz JC, Jiménez JR, Puyol MR, Puyol DR, Kitamura M, Cazaña FJ. Human renal mesangial cells are a target for the anti-inflammatory action of 9-cis retinoic acid. Br J Pharmacol 131: 1673-1683, 2000.
21. Martinez JR, Cowley BD, Gattone 2nd VH, Nagao S, Yamaguchi T, Kaneta S, Takahashi H, Grantham JJ. The effect of paclitaxel on the progression of polycystic kidney disease in rodents. Am J Kidney Dis 29: 435-444, 1997.
22. Mrug M, Zhou J, Woo Y, Cui X, Szalai AJ, Novak J, Churchill GA, Guay-Woodford LM. Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. Kidney Int 73: 63-76, 2008.
23. Nagao S, Nishii K, Yoshihara D, Kurahashi H, Nagaoka K, Yamashita T, Takahashi H, Yamaguchi T, Calvet JP, Wallace DP. Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+ rat. Kidney Int 73: 269-277, 2008.
24. Nagao S, Yamaguchi T, Kusaka M, Maser RL, Takahashi H, Cowley BD, Grantham JJ. Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease. Kidney Int 63: 427-437, 2003.
25. Nagao S, Kusaka M, Nishii K, Marunouchi T, Kurahashi H, Takahashi H, Grantham JJ. Androgen receptor pathway in rats with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 16: 2052-2062, 2005.
26. Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, Li X, Elia AE, Lu W, Brown EM, Quinn SJ, Ingber DE, Zhou J. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 33: 129-137, 2003.
27. Nauli SM, Rossetti S, Kolb RJ, Alenghat FJ, Consugar MB, Harris PC, Ingber DE, Loghman-Adham M, Zhou J. Loss of polycystin-1 in human cyst-lining epithelia leads to ciliary dysfunction. J Am Soc Nephrol 17: 1015-1025, 2006.
28. Nezbedova P, Brtko J. 1Alpha,25-dihydroxyvitamin D3 inducible transcription factor and its role in the vitamin D action. Endocr Regul 38: 29-38, 2004.
29. Papi A, Rocchi P, Ferreri AM, Guerra F, Orlandi M. Enhanced effects of PPARgamma ligands and RXR selective retinoids in combination to inhibit migration and invasiveness in cancer cells. Oncol Rep 21: 1083-1089, 2009.
30. Pelton PD, Patel M, Demarest KT. Nuclear receptors as potential targets for modulating reverse cholesterol transport. Curr Top Med Chem 5: 265-282, 2005.
31. Pogenberg V, Guichou JF, Vivat-Hannah V, Kammerer S, Pérez E, Germain P, de Lera AR, Gronemeyer H, Royer CA, Bourguet W. Characterization of the interaction between retinoic acid receptor/retinoid X receptor (RAR/RXR) heterodimers and transcriptional coactivators through structural and fluorescence anisotropy studies. J Biol Chem 280: 1625-1633, 2005.
32. Qian Q, Li A, King BF, Kamath PS, Lager DJ, Huston 3rd J, Shub C, Davila S, Somlo S, Torres VE. Clinical profile of autosomal dominant polycystic liver disease. Hepatology 37: 164-171, 2003.
33. Qian Q, Du H, King BF, Kumar S, Dean PG, Cosio FG, Torres VE. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 19: 631-638, 2008.
34. Ramasubbu K, Gretz N, Bachmann S. Increased epithelial cell proliferation and abnormal extracellular matrix in rat polycystic kidney disease. J Am Soc Nephrol 9: 937-945, 1998.
35. Riera M, Burtey S, Fontés M. Transcriptome analysis of a rat PKD model: Importance of genes involved in extracellular matrix metabolism. Kidney Int 69: 1558-1563, 2006.
36. Rizzo G, Renga B, Mencarelli A, Pellicciari R, Fiorucci S. Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr Drug Targets Immune Endocr Metabol Disord 5: 289-303, 2005.
37. Roffeis J, Hornung D, Kuhn H, Walther M. 15-Lipoxygenase-2 is differentially expressed in normal and neoplastic ovary. Eur J Cancer Prev 16: 568-575, 2007.
38. Rulifson IC, Karnik SK, Heiser PW, ten Berge D, Chen H, Gu X, Taketo MM, Nusse R, Hebrok M, Kim SK. Wnt signaling regulates pancreatic beta cell proliferation. Proc Natl Acad Sci USA 104: 6247-6252, 2007.
39. Schäfer K, Gretz N, Bader M, Oberbäumer I, Eckardt KU, Kriz W, Bachmann S. Characterization of the Han:SPRD rat model for hereditary polycystic kidney disease. Kidney Int 46: 134-152, 1994.
40. Schubert SW, Kardash E, Khan MA, Cheusova T, Kilian K, Wegner M, Hashemolhosseini S. Interaction, cooperative promoter modulation, and renal colocalization of GCMa and Pitx2. J Biol Chem 279: 50358-50365, 2004.
41. Shanley TP, Cvijanovich N, Lin R, Allen GL, Thomas NJ, Doctor A, Kalyanaraman M, Tofil NM, Penfil S, Monaco M, Odoms K, Barnes M, Sakthivel B, Aronow BJ, Wong HR. Genome-level longitudinal expression of signaling pathways and gene networks in pediatric septic shock. Mol Med 13: 495-508, 2007.
42. Shappell SB, Boeglin WE, Olson SJ, Kasper S, Brash AR. 15-Lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol 155: 235-245, 1999.
43. Song X, Di Giovanni V, He N, Wang K, Ingram A, Rosenblum ND, Pei Y. Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Hum Mol Genet 18: 2328-2343, 2009.
44. Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia 7: 280-293, 2005.
45. Tang DG, Bhatia B, Tang S, Schneider-Broussard R. 15-Lipoxygenase 2 (15-LOX2) is a functional tumor suppressor that regulates human prostate epithelial cell differentiation, senescence, and growth (size). Prostaglandins Other Lipid Mediat 82: 135-146, 2007.
46. Traber MG. Vitamin E, nuclear receptors and xenobiotic metabolism. Arch Biochem Biophys 423: 6-11, 2004.
47. Vandorpe DH, Chernova MN, Jiang L, Sellin LK, Wilhelm S, Stuart-Tilley AK, Walz G, Alper SL. The cytoplasmic C-terminal fragment of polycystin-1 regulates a Ca2+-permeable cation channel. J Biol Chem 276: 4093-4101, 2001.
48. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP. Inhibition of mTOR with sirolimus slows disease progression in Han: SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 21: 598-604, 2006.
49. Wahl PR, Le Hir M, Vogetseder A, Arcaro A, Starke A, Waeckerle-Men Y, Serra AL, Wuthrich RP. Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease. Nephrology (Carlton) 12: 357-363, 2007.
50. Wente W, Brenner MB, Zitzer H, Gromada J, Efanov AM. Activation of liver X receptors and retinoid X receptors induces growth arrest and apoptosis in insulin-secreting cells. Endocrinology 148: 1843-1849, 2007.
51. Xiao JH, Ghosn C, Hinchman C, Forbes C, Wang J, Snider N, Cordrey A, Zhao Y, Chandraratna RA. Adenomatous polyposis coli (APC)-independent regulation of beta-catenin degradation via a retinoid X receptor-mediated pathway. J Biol Chem 278: 29954-29962, 2003.
52. Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int 60: 1645-1657, 2001.
53. Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, Grantham JJ. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 63: 1983-1994, 2003.
54. Yamaguchi T, Hempson SJ, Reif GA, Hedge AM, Wallace DP. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 17: 178-187, 2006.
55. Yamazaki K, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Kanemura N, Araki H, Tsurumi H, Kojima S, Weinstein IB, Moriwaki H. Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells-phosphorylated RXR alpha is a critical target for colon cancer management. Gut 56: 1557-1563, 2007.
56. Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol 13: 2508-2516, 2002.
57. Yoder BK, Mulroy S, Eustace H, Boucher C, Sandford R. Molecular pathogenesis of autosomal dominant polycystic kidney disease. Expert Rev Mol Med 8: 1-22, 2006.
58. Zhang-Gandhi CX, Drew PD. Liver X receptor and retinoid X receptor agonists inhibit inflammatory responses of microglia and astrocytes. J Neuroimmunol 183: 50-59, 2007.